Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02467400 · ClinicalTrials.gov registry record · Early Phase 1

Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism

A Early Phase 1 study, sponsored by Mayo Clinic.

Completed
Registry status
Early Phase 1
Development phase
165
Enrollment target

NCT02467400: Completed Early Phase 1 study, sponsored by Mayo Clinic.

NCT02467400 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 165 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (211% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02467400, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Early Phase 1
Development phase
165 participants
Enrollment target

Study Summary

This study is designed to answer the question as to whether the sympathetic nervous system is an important determinant of bone metabolism in humans.

Primary Outcome

Serum bone formation marker (PINP)/serum bone resorption marker (CTX)

Interventions

  • DRUG placebo
  • DRUG Atenolol
  • DRUG Propranolol
  • DRUG Nebivolol

Trial Details

FieldValue
Enrollment Target 165 participants
Start Date 2015-07-01
Est. Completion 2018-04-01
Phase Early Phase 1
Mayo Clinic

2,844 total trials

What the finished NCT02467400 record still lists

NCT02467400 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (211% higher).

The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.

NCT02467400 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02467400 about?

NCT02467400 is a clinical study titled "Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism". This study is designed to answer the question as to whether the sympathetic nervous system is an important determinant of bone metabolism in humans.

What is the current status of trial NCT02467400?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 165 participants. The study started on 2015-07-01. Estimated completion is 2018-04-01.

What interventions are being tested in trial NCT02467400?

The interventions under investigation include: placebo (DRUG), Atenolol (DRUG), Propranolol (DRUG), Nebivolol (DRUG).

Who is sponsoring clinical trial NCT02467400?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02467400's enrollment target sits among peer trials

165 80th of 2000 higher than 1,919 of 2,000 other Early Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02387255 · 165 participants

    Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms

  • NCT03351348 · 165 participants · Phase 3

    Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control

  • NCT03830320 · 165 participants · Phase 1

    Positron Emission Tomography (PET) Imaging of Thrombosis

  • NCT04289571 · 165 participants · Phase 1

    Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02467400, the US trial registry maintained by the National Library of Medicine. NCT02467400 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.